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Abstract 
Background: During pregnancy, the mouse mammary ductal epithelium branches and grows into the surrounding 
stroma, requiring extensive extracellular matrix (ECM) and tissue remodelling. It therefore shows parallels to cancer 
invasion. We hypothesised that similar molecular mechanisms may be utilised in both processes, and that assessment 
of the stromal changes during pregnancy-associated branching may depict the stromal involvement during human 
breast cancer progression.
Methods: Immunohistochemistry (IHC) was employed to assess the alterations within the mouse mammary gland 
extracellular matrix during early pregnancy when lateral branching of the primary ductal epithelium is initiated. Pri-
mary mouse mammary fibroblasts from three-day pregnant and age-matched non-pregnant control mice, respec-
tively, were 3D co-cultured with mammary epithelial cells to assess differences in their abilities to induce branching 
morphogenesis in vitro. Transcriptome analysis was performed to identify the underlying molecular changes. A 
signature of the human orthologues of the differentially expressed matrisome RNAs was analysed by Kaplan–Meier 
and multi-variate analysis in two large breast cancer RNA datasets (Gene expression-based Outcome for Breast cancer 
Online (GOBO) und Kaplan–Meier Plotter), respectively, to test for similarities in expression between early-pregnancy 
mouse mammary gland development and breast cancer progression.
Results: The ECM surrounding the primary ductal network showed significant differences in collagen and base-
ment membrane protein distribution early during pregnancy. Pregnancy-associated fibroblasts (PAFs) significantly 
enhanced branching initiation compared to age-matched control fibroblast. A combined signature of 64 differentially 
expressed RNAs, encoding matrisome proteins, was a strong prognostic indicator of distant metastasis-free survival 
(DMFS) independent of other clinical parameters. The prognostic power could be significantly strengthened by using 
only a subset of 18 RNAs (LogRank P ≤ 1.00e−13; Hazard ratio (HR) = 2.42 (1.8–3.26); p = 5.61e−09). The prognostic 
power was confirmed in a second breast cancer dataset, as well as in datasets from ovarian and lung cancer patients.
Conclusions: Our results describe for the first time the early stromal changes that accompany pregnancy-associated 
branching morphogenesis in mice, specify the early pregnancy-associated molecular alterations in mouse mammary 
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Background
Stromal-epithelial interactions control epithelial cell 
growth during normal organ development and cancer 
progression [1]. Fibroblasts, as a major stromal cell 
type, play key roles in controlling development and 
cancer progression-associated histological changes 
[2]. While normal fibroblasts can suppress tumour 
growth, cancer-associated fibroblasts (CAFs) have been 
reported to support or even induce growth, invasion 
and metastasis [2, 3]. However, CAFs are highly het-
erogeneous and can even suppress tumour growth [4, 
5]. No single biomarker is so far described that would 
either clearly define CAFs or identify a specific tumour 
suppressive or supportive role [5]. Their mechanisms 
of action are accordingly also highly complex, affect-
ing growth factor-induced proliferation, remodelling 
of ECM and neo-vascularisation [2]. Thus, our under-
standing of how fibroblasts control cancer progression 
is still limited. It has therefore been suggested that in 
order to fully comprehend the role(s) of CAFs during 
cancer progression one first needs to understand the 
roles of normal fibroblasts in controlling epithelial cell 
growth [6].
The developing mouse mammary gland is an excellent 
model system to study stromal influence on epithelial 
growth as it develops mainly postnatally, showing sig-
nificant morphological changes. Furthermore, remod-
elling processes similar to those seen during breast 
cancer progression are also observed during normal 
mammary branching morphogenesis [7, 8]. At puberty, 
a rudimentary epithelium grows into the surrounding 
mammary fat pad helped by highly proliferative termi-
nal end buds (TEB), forming a branched primary ductal 
network behind them [9]. While ECM at the growth 
front of TEBs mainly contains a thin layer of hyalu-
ronic acid-rich basement membrane (BM), ECM of the 
neck region is defined by a thick surrounding layer of 
fibrous collagenous BM/ECM [7, 9], which continues 
along the developing milk ducts. During pregnancy, 
these ducts form lateral side branches and alveoli, a 
process which requires remodelling of the surrounding 
ECM; specifically, breakdown of existing BM/collagen 
sheath and formation of a new BM and collagen net-
work [10]. This process could therefore be described as 
‘controlled invasion’. Epithelial-stromal interactions are 
crucial for these morphological changes to occur [1] 
and fibroblasts play an essential part [10, 11]. However, 
our understanding of the molecular processes involved 
and how fibroblasts enable ductal branching remains 
limited.
By enzymatically isolating TEB and mammary ducts, 
we previously identified the involvement of axon-guid-
ance proteins [12] as well as the involvement of BM pro-
teins fibulin-2 (FBLN2) and versican (VCAN) in pubertal 
ductal development [13, 14]. We also recently established 
a method, which enabled us to carry out whole-genome 
transcriptome analysis on RNA from very small popula-
tions of freshly isolated, non-cultured mammary fibro-
blasts using linear amplification [15].
Here we used this method to characterise the mam-
mary fibroblast transcriptome of 3 day-pregnant and age-
matched control mice. We focussed on RNAs encoding 
proteins of the matrisome, which comprises core ECM-
proteins, ECM-modifying enzymes, growth factors, and 
matricellular proteins [16]. The identified RNAs describe 
a network of growth factor activation, protease expres-
sion, collagen sheath breakdown, and induced ECM/
BM formation, thereby identifying potential new control 
mechanisms for epithelial outgrowth. Consistent with 
our hypothesis, this pregnancy-associated RNA signa-
ture of matrisome genes was able to significantly predict 
distant metastasis-free and recurrence-free survival in a 
dataset of 1881 human breast cancers [17] independent 
of other clinical parameters, as well as progression-free 
survival in patients with lung or ovarian cancer. Our data 
therefore sheds important new light onto potential regu-
lators of breast cancer progression and provides a poten-
tial new matrisome-based prognostic marker for the risk 
of developing distant metastases.
Material and methods
Animal husbandry
Mice (strain C57BL/6) were kept in conventional M3 
cages bedded with wood chips and paper nesting material 
in a temperature-controlled environment at 21 ± 1  °C, 
45–55% humidity on a 12-h light/dark cycle. Food and 
water were provided ad  libitum. Mice were allowed a 
7-day acclimatisation period after arrival on site prior to 
experimental use.
Fibroblast enrichment
Primary mammary fibroblast-enriched extracts were 
isolated as previously described [15]. Briefly, pregnant 
mice were sacrificed by schedule 1 method three days 
fibroblasts, and identify a matrisome signature as a strong prognostic indicator of human breast cancer progression, 
with particular strength in oestrogen receptor (ER)-negative breast cancers.
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after first plug formation together with their virgin age-
matched control littermates (12–13  weeks of age). Tho-
racic and inguinal mammary glands from one flank were 
dissected and collected into DMEM-F12 medium (Life 
Technologies, Paisley UK), while glands from the other 
flank were processed for paraffin-embedding. Glands 
were finely minced and digested with 2.5  mg/ml (w/v) 
collagenase type II (Sigma-Aldrich Ltd., St. Louis, USA) 
and Trypsin (0.2%) (Sigma) in DMEM-F12 medium 
for 30  min, using a shaking incubator set at 37  °C and 
100 rpm. Free genomic DNA was removed using 2units/
ml DNase I (Sigma), cells were centrifuged and resus-
pended thoroughly in serum-free DMEM-F12 medium. 
Epithelial cells were separated from other cells by a series 
of pulsed centrifugations (5–6 times) and fibroblast-
containing supernatant was then incubated in a 100 mm 
tissue culture dish for 1  h at 37  °C and 5%  CO2. Fibro-
blasts that stuck to the plate were washed 3 times and 
were either cultured or further purified for RNA extrac-
tion and amplification. For microarray analysis cells were 
gently trypsinised using 0.05% Trypsin/EDTA (Thermo 
Fisher Scientific, Waltham, MA, USA) and  CD45pos con-
taminants were removed using a CD45-Biotin antibody 
(Biolegend, San Diego, USA, Clone 30-F11) in conjunc-
tion with an EasySep Biotin Selection system (Stem Cell 
Technologies, Vancouver, Canada). The  CD45neg fibro-
blasts were collected by centrifugation and directly used 
for RNA extraction.
Tissue culture
EpH4 cells and primary fibroblasts were grown at 37  °C 
in a humidified atmosphere with 5%  CO2. Cells were 
grown in DMEM-F12/10% FBS (Thermo Fisher Scien-
tific) media supplied with 2  mM L-glutamine (Thermo 
Fisher Scientific), 100 U/ml penicillin (Thermo Fisher 
Scientific) and 100  µg/ml streptomycin (Thermo Fisher 
Scientific).
Epithelial‑fibroblast co‑culture
Growth factor-reduced Matrigel™ (BD Biosciences, 
Oxford, UK) was thawed on ice overnight. 50  μl were 
added to each well of a 96-well plate to cover the surface 
of the well and incubated at 37 °C for 30 min to solidify. 
5000 cells per well (EpH4 cells and fibroblasts 1:1) were 
re-suspended in DMEM-F12/serum-free media mixed 
with 5% Matrigel and plated on top of the Matrigel lay-
ers. Cells were grown in triplicate in serum-free media 
overnight. Media was then replaced every other day with 
DMEM-F12/5% FBS for 7–8  days before microscopic 
analysis.
For structural analysis, spheroids were categorized 
according to their size and degree of branching to 5 dis-
tinct types: small unbranched, small branched, large 
unbranched, large branched and large highly branched 
(structures with secondary branching). For quantifica-
tion, 10 × bright field objective was employed to count 
the structures directly from under the microscope in 4 
representative fields per condition in triplicate experi-
ments to avoid local differences within the 3D culture. 
Representative pictures were captured with 20 × objec-
tive for reference. Statistical analysis was performed on 
the mean percentage of the different structures between 
the conditions using the student T-test function in Excel.
RNA isolation and amplification
RNA was extracted and amplified as described previously 
[15], using Direct-zol™ RNA MiniPrep (Zymo Research, 
Irvine, USA) for cultured cells (> 10,000 cells) or Direct-
zol™ RNA MicroPrep (Zymo Research) for freshly iso-
lated fibroblasts (500–2,000 cells) as per manufacturer’s 
instructions. RNA was eluted in RNase-free water and 
quantified using the NanodropND-1000 Spectropho-
tometer (Thermo Fisher Scientific). Quality was assessed 
using an Agilent bioanalyser (Agilent Technologies). An 
RNA 6000 Pico kit (Agilent, South Queensferry, UK) 
was used for quantification and assessment of RNA from 
small cell numbers.
RNA amplification was performed using Ovation® 
PicoSL WTA Systems V2 kit (NuGEN, San Carlos, USA) 
as per manufacturer’s instructions with slight modifica-
tions as described previously [15]. Briefly, equal volumes 
of RNA samples from individual pregnant and non-
pregnant mice (minimum concentration 500  pg in 1  µl 
of maximum volume) in 5 µl of nuclease-free water were 
subjected to a cycle of 1st strand synthesis followed by a 
cycle of  2nd strand synthesis. Double stranded product 
was separated from excess primers using the included 
magnetic bead-based system. For amplification, purified 
double stranded products were subjected to the SPIA 
amplification system (with RNase H and DNA polymer-
ase) and the amplified ss-cDNA product was further 
purified using a PCR purification kit (QIAGEN Ltd., 
Manchester, UK) as per manufacturer’s instructions. 
Pure amplified product was reconstituted in nuclease-
free water and quantified using a NanodropND-1000 
Spectrophotometer (Thermo Fisher Scientific). Qual-
ity and distribution of the RNA and subsequent cDNA 
curves were assessed using an Agilent Bioanalyser (Agi-
lent Technologies).
Microarray hybridisation
After amplification, cDNA samples were labelled using 
an Encore Biotin Module (NuGEN) as per manufactur-
er’s instructions. 1.5 µg of cDNA was subjected to uracil-
DNA glycosylase (UNG) treatment to remove uracil base 
incorporation from the amplification process, followed 
Page 4 of 19Ibrahim et al. Breast Cancer Res           (2021) 23:90 
by one step of biotin incorporation. Samples were puri-
fied with a PCR purification kit (QIAGEN Ltd.) and sam-
ples were kept at − 20 °C until hybridisation.
cDNA samples were hybridised to MouseWG-6 v2.0 
Expression BeadChip arrays (Illumina Inc., Little Ches-
terford, UK) as per manufacturer’s instructions. 1.5 μg of 
labelled cDNA of each sample in 10  μl was mixed with 
20  μl of hybridisation buffer in nuclease-free tubes and 
pre-heated at 65 °C in a thermocycler for 5 min. Six pre-
heated samples (three pregnancy-associated and three 
control virgin) were incubated in an incubation cham-
ber with humidity control buffer at 48  °C for 16  h. The 
bead-chip was carefully de-sealed, washed and blocked 
in E1 blocking buffer for 10 min with rocking. The bead-
chip was blocked in E1 buffer with a 1:1000 dilution of 
streptavidin-Cy3 (of 1 mg/ml) for 10 min, followed by a 
washing step for 5 min. Finally, the bead-chip was spun at 
275 g for 4 min at 25 °C to dry and scanned with a micro-
array scanner (Illumina Inc.) via the decode file (.dmap) 
provided with the chip.
Microarray analysis
Scanner data was transferred to Genome Studio software 
(Illumina Inc.) for hybridisation quality control and gen-
eral data analysis. Quality control included sample-inde-
pendent and sample-dependent assessments. Exported 
data were further analysed using R-software/ranking 
products (RP) module [18] (The R Foundation).
qRT‑PCR
cDNAs were produced with the RNA amplification kit 
or with Superscript II (Thermo Fisher Scientific). Each 
reaction mixture contained 1  μl (0.25  μM) probe, 1  μl 
primers mixture (7.2  μM of both forward and reverse 
primers), 10  μl of 2 × LightCycler® 480 TaqMan Mas-
ter Mix (Roche, Basel, Switzerland), 5 μl diluted sample 
and nuclease-free water to a final reaction volume of 
20  μl. Primers  (Sigma): Col3a1: Fwd 5′-gtcctgctggaaa-
ggatgg-3′, Rev 5′-ctggaggtccaggcagtc-3′ (Probe #80); 
Col18a1: Fwd 5′-gctcaccagtttggtcttgc-3′, Rev 5′-ccacctc-
ctcagcaacattc-3′ (Probe #21); Gpc1: Fwd 5′-aggcagaga-
tctcgggtga-3′, Rev 5′-gctctccagctccattcg-3′ (Probe #25); 
Alx4: Fwd 5′-gacacactaccctgatgtgtatgc-3′, Rev 5′-tcc-
ctctttcgccacttg-3′ (Probe #32); Wisp2: Fwd 5′-cccactgatc-
catcttctgg-3′, Rev 5′-tgtccaaggacaggcacag-3′ (Probe #6); 
Tnc: Fwd 5′-gggctatagaacaccgatgc-3′, Rev 5′-catttaagtttc-
caatttcaggttc-3′ (Probe #76); Vcan: Fwd 5′-cactggctgtg-
gatggtg-3′, Rev 5′-cagcggcaaagttcagagt-3′ (Probe #62), 
β-actin: Fwd 5′-aaggccaaccgtgaaaagat-3′, Rev 5′-gtggtac-
gaccagaggcatac-3′ (Probe #56). PCR reaction was car-
ried out using a LightCycler® 480 Instrument (Roche) 
under standard conditions. Relative RNA expression was 
normalised to the house-keeping gene actin and the data 
were presented as % of actin.
Haematoxylin–eosin staining
5  μm FFPE-mouse mammary gland sections were 
immersed 3 × in xylene for 5  min, 3 × in absolute etha-
nol for 2 min, then rinsed in distilled water. After incu-
bation in haematoxylin (Sigma) for 2  min, slides were 
washed under running tap water and dipped in Scott’s 
Tap water for 30 s. Slides were transferred to eosin (Dako, 
Eli, UK) for 2  min and rinsed thoroughly using run-
ning tap water. Stained tissue sections were de-hydrated 
through increasing concentrations of ethanol, immersed 
in fresh xylene for 3 min and finally mounted using Per-
tex mounting medium (Cell Path, Newtown, UK).
Immunohistochemistry (IHC)
IHC was generally performed as described in [19]. 5 μm 
sections were routinely cut from formalin-fixed, paraffin 
wax-embedded mammary glands. Sections were depar-
affinised for 10 min in two changes of xylene, hydrated in 
descending concentrations of ethanol and then immersed 
in water. Sections were incubated in 3% (v/v) hydro-
gen peroxide for 10  min to quench endogenous peroxi-
dases; antigen retrieval was then performed using 1 mM 
EDTA buffer (pH 8) under high pressure. Sections were 
subjected to blocking step using pre-diluted 2.5% horse 
serum for 20 min, then incubated with primary antibody 
for 2 h at RT in a humidified chamber. All antibodies were 
diluted to their final concentrations using Antibody Dilu-
ent (Dako). Sections were then washed with PBS-0.1% 
Tween 20 (Sigma) three times for 10 min and incubated 
with polyclonal anti-rabbit (HRP labelled) second-
ary antibody (Vector Laboratories Ltd., Peterborough, 
UK) for 30  min. Primary antibodies used: anti-FBLN2 
1:10,000 [20]; anti-VCAN 1:150 (Millipore/Chemicon 
AB1033, Burlington USA); anti-Col I (Abcam, Cam-
bridge, UK,  #ab21286); anti-Col IV (Abcam, #ab6586), 
anti-Col VI (Millipore/Sigma, #ab7821); anti-AGRN 
(R&D Systems, Abingdon, UK;  #AF550); anti-FBLN5 
(Abcam, #ab109428); anti-BMP1 (Abcam, #ab118520); 
anti-ALX4 1:150 (Sc-33643, Santa Cruz, Dallas, USA). 
Sections were washed with PBS-0.1% Tween 20 three 
times for 10  min and incubated in diluted (1 drop in 
1  ml of Antibody Diluent) DAB + Chromogen (Vector 
Laboratories Ltd.) for 4 min. Stained tissue sections were 
counterstained with haematoxylin, dehydrated through 
ascending concentrations of ethanol and cleared with 
xylene before mounting with cover slips using Pertex 
mounting medium (Cell Path). Sections were imaged and 
scanned using a NanoZoomer Digital Pathology scanner 
(Hamamatsu Photonics UK Limited,  Welwyn Garden 
City, UK) at 20 × magnification.
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Kaplan–Meier analysis
Kaplan–Meier analyses were performed using the Gene 
Expression-Based Outcome for Breast Cancer Online 
(GOBO) tool [17] from Lund University and KM-Plot-
ter [21]. This tool uses RNA expression data from 1881 
breast tumour samples generated on Affymetrix U133A 
microarrays in 11 independent studies that are freely 
available from the Gene Expression Omnibus (GEO; 
please refer to [17] for more detail). To assess prognos-
tic power of individual RNAs (Kaplan–Meier analysis), 
the ‘Gene Set Analysis—Tumors’ function within GOBO 
was used. Distant metastasis-free survival (DMFS) and 
recurrence-free survival (RFS) were selected as end 
points, respectively, with a 10-year cut-off. The selected 
number of quantiles was set to ‘2’. LogRank p-values were 
adjusted for multiple comparisons across all genes and 20 
predefined subgroups of the total cohort using the Ben-
jamini–Hochberg method, implemented in the p.adjust 
function of R [22]. Genes which remained significant in 
any subgroup were included in the final 18-gene signa-
ture. To assess ability of any of the identified RNA signa-
tures for breast cancer cohort stratification, the ‘Sample 
Prediction’ analysis function within the GOBO analysis 
tool was used. ‘Day 3 pregnancy vs control’ fold-change 
ratios were used as expression centroids within the sig-
natures (averages were used where more than one probe 
per RNA was present). Kaplan–Meier analysis was per-
formed using correlative centroid prediction (Pearson) 
with a cut-off of 0 (all patients with expression profiles 
positively correlated to the direction and magnitude 
of changes observed in early pregnancy were included 
in one group; negative correlations formed the other 
group). DMFS or RFS were selected as end points with 
a 10-year cut-off. LogRank p-values of < 0.05 were again 
regarded as significant. Multivariate analyses were per-
formed in the presence of ER-status, LN-status, grade, 
age and tumour size. Multivariate analyses in GOBO are 
implemented using the survival library in R [17]).
For KM-Plotter analysis, patient cohorts were split 
using combined median expression levels of all probes 
against the 18-gene signature with negative weighting for 
those genes associated with good prognosis in GOBO. 
Again, a 10-year cut-off was used, with DMFS (breast 
cancer set) and progression-free survival (all other cancer 
sets) chosen as endpoint.
Results
Early pregnancy induces a loosening collagen sheath 
and BM protein expression
The first microscopically observable histological changes 
occur two to three days after conception [13], includ-
ing an overall denser stromal adipose tissue and more 
prominent ECM layer (Fig.  1A). To test whether these 
morphological changes were accompanied by an altered 
ECM protein expression, candidate proteins of the colla-
gen sheath and BM were assessed by IHC in mammary 
glands of three days pregnant and age-matched virgin 
mice. Staining for fibrillary collagen (COL) I and COLVI 
was strong and highly localised around the ducts of non-
pregnant adult mice. This staining appeared to become 
weaker and less defined in the glands of early pregnant 
mice (Fig. 1B). In contrast, bone morphogenetic protein 
(BMP) 1, involved in formation of new collagen fibrils, 
was predominantly detected around ductal epithelium 
of pregnant mice. This suggests a general loosening of 
the fibrillary collagen sheath at onset of pregnancy as 
new collagen bundles form. BM components like agrin 
(AGRN) and FBLN2 were noticably up-regulated in 
early-pregnancy mammary gland sections (Fig.  1B), 
consistent with our previous observation of upregulated 
FBLN2 and VCAN during early pregnancy [13]. Con-
trastingly, FBLN5 was more abundant around ducts from 
non-pregnant mice. Similar results were observed in the 
 3rd gland of the same animals (Additional file  1: Figure 
S1). These results highlight widespread ECM remod-
elling and fibrillar collagen sheath loosening ahead of 
pregnancy-induced lateral ductal branch morphogenesis. 
Since fibroblasts play key roles in ECM remodelling, we 
next focussed our attention on the fibroblasts within the 
mammary gland of early pregnant mice.
Pregnancy‑associated fibroblasts induce branching 
of epithelial cells in vitro
We hypothesised that if fibroblasts were involved in ini-
tiation of ductal branching in early pregnancy, isolated 
fibroblasts from early pregnant mice (pregnancy-asso-
ciated fibroblasts (PAFs)) might initiate branching mor-
phogenesis in  vitro. We therefore isolated mammary 
fibroblast-enriched extracts from 3  days-pregnant and 
age matched non-pregnant control littermates. Both 
fibroblast-enriched extracts were initially cultured on 
plastic for 2–3 passages before co-culturing with mouse 
mammary epithelial EpH4 cells in Matrigel. While EpH4 
cells alone formed mostly small spheroidal structures 
(Fig. 2), EpH4 cells grown in the presence of adult virgin 
mouse fibroblasts showed enlarged acini with limited 
branching. When EpH4 cells were grown in the presence 
of PAFs, significantly more enlarged, highly branched 
structures were detected (11% vs < 2%; P = 0.001; 
Additional file  2: Table  S1). Hence, isolated PAFs and 
mammary fibroblasts from nulliparous mice showed sig-
nificantly different branch initiation activities in  vitro, 
which implied an altered gene expression pattern in these 
cells.
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Pregnancy induces a distinct RNA expression pattern 
in mouse mammary fibroblasts
We next aimed to identify the potential molecular mech-
anisms that could enable mouse mammary fibroblasts to 
induce branching morphogenesis in vivo by using whole 
genome transcriptome analysis. Freshly isolated, non-
cultured primary fibroblast-enriched extracts were used 
to reflect the in  vivo situation more closely. These were 
again isolated from inguinal and thoracic mammary 
glands dissected from one flank of 3 days-pregnant mice 
and from age-matched non-pregnant littermates. Preg-
nancy-associated morphological changes were confirmed 
by staining contralateral glands for FBLN2 as previously 
described [13], while increased COLIV staining con-
firmed further BM-associated changes (Additional file 3: 
Figure S2).
Analysis of markers for fibroblasts (Platelet-derived 
growth factor-receptor 1 (Pdgfra), Col1a1, Col1a2, ser-
pin family H member 1 (Serpinh1)/heat-shock protein 47 








adult virgin day 3 pregnancy
A P3 A P3 B P3 C
Ctrl A Ctrl B Ctrl C
Fig. 1 (A) Hematoxylin/eosin staining of representative (n = 3 animals) 3-days pregnant mouse inguinal mammary glands (P3 A‑C) show the 
histological changes compared to age-matched adult virgin glands (Ctrl A‑C) of denser stromal adipose tissue () and wider ECM layer around 
epithelium (). Scale bars are 250 µm (B) Immunohistochemical analysis of 3-days pregnant mouse (n = 1 animal,  4th gland) mammary gland and 
age-matched adult virgin glands showing the changes of matrix- and basement membrane-associated proteins (COLI, COLVI, BMP1, FBLN2, FBLN5, 
and AGRN). Scale bars are 50 µm
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myoepithelial cells (smooth muscle actin (Acta2)), myoep-
ithelium (keratin (Krt) 5 and 14), luminal epithelium 
(Krt8 and 18), vascular endothelium (platelet endothe-
lial cell adhesion molecule (Pecam1)/Cd31, VE-cadherin 
(Cdh5)), macrophages (EGF module-containing mucin-
like hormone receptor (Emr1)), and leukocytes (Cd45/
Protein tyrosine phosphatase, receptor type, C (PtprC)) 
confirmed strong enrichment of fibroblast-associated 
RNAs in our extracts from both pregnant and virgin mice, 
with low cross-contamination with other cell types tested 
(Additional file  4: Figure S3). Differentially expressed 
RNAs were then ranked according to their p-value. 897 
probes showed a change with p-value < 0.05, represent-
ing 840 genes. Table  1 shows the 50 most significantly 
changed probes ranked by p-values and grouped into up- 
and down-regulated genes (for full list please see Addi-
tional file 5: Table S2). Two of the top four differentially 
expressed RNAs encoded proteins already known to be 
expressed in mammary stroma of pubertal and pregnant 
mice, which are necessary for mammary gland outgrowth 
and/or branching: glucocorticoid receptor DNA-binding 
factor 1 (Grlf1) [23], and aristaless-like 4 (Alx4) [24]. The 
list further included the proteoglycan Vcan, which we 
had previously described to be specifically detected in 
the stroma of pubertal outgrowing mammary epithelium 
and during early pregnancy [13]. IHC confirmed this spe-
cific expression, as well as expression of ALX4 protein in 
stromal cells surrounding ductal epithelia during early 
pregnancy (Fig. 3A; Additional file 6: Figure S4). Differ-
ential expression was further confirmed by qRT-PCR for 
a selection of identified RNAs (Alx4, Gpc1, Vcan, Wisp2/
Cnn5), though Wisp2/Ccn5 did not reach statistical sig-
nificance (P = 0.19) (Fig. 3B).
Pregnancy‑associated gene expression changes identify 
an ECM‑remodelling programme
To identify those factors most likely to affect the 
described morphological changes seen in the mammary 
gland of early pregnant mice, we next focussed on the 
RNAs encoding proteins of the matrisome as defined 
previously [16, 25]. Filtering the 897 probes identified 74 
probes (8.24%), representing 64 differentially expressed 
core-matrisome and matrisome affiliated genes (Table 2). 
Again, qRT-PCR confirmed differential expression of 
selected RNAs (Col18a1, Col3a1, Tnc) within this table 
(Fig.  3C). This list described a complex programme 
































Fig. 2 Percentage of specified epithelial 3D-growth patterns of EpH4 cells cultured within Matrigel (Ctrl) or co-cultured with mammary fibroblasts 
from 3-days pregnant (P3) or age-matched adult virgin mice (V12). Bars represent standard errors (n = 3 replicate experiments). Images below show 
representative images for each 3D structure classification of small spheroids (left), small branched (more elongated;  2nd from left), large spheroids 
(at least 5-times larger than small spheroids; middle), large branched (branched but compact;  2nd from right) to large highly branched structures 
(branched and extended; right). Scale bars are 50 µm. The p-value (0.001) shows the statistically significant difference in the number of large, highly 
branched structures between P3 and virgin control (Student T-test)
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Table 1 Top 50 differentially expressed RNAs (using RankP)
Probe_ID Gene symbol p‑values Fold change Preg/Ctrl Median Preg Median Ctrl
ILMN_2766542 Grlf1 0.0001 5.57 571.11 102.54
ILMN_1241214 Myh4 0.0001 5.05 293.53 58.09
ILMN_2487824 Alx4 0.0001 4.23 666.18 157.52
ILMN_2635784 Gpc1 0.0001 3.74 744.07 199.17
ILMN_2936517 Bcl2l2 0.0002 4.74 749.98 158.23
ILMN_1239430 Mrc1 0.0002 3.25 331.29 101.97
ILMN_2647028 Copz2 0.0002 2.84 729.06 256.57
ILMN_2930819 Acd 0.0003 3.20 1064.86 333.05
ILMN_1247540 Vcan 0.0003 3.10 435.82 140.46
ILMN_2945275 Rbm15 0.0005 2.84 427.28 150.19
ILMN_2636443 Bcl2l2 0.0006 3.49 857.62 245.92
ILMN_2709782 Mtap2 0.0008 3.98 205.62 51.69
ILMN_1258929 2610110G12RIK 0.0008 3.60 214.99 59.71
ILMN_1230753 B230399E16RIK 0.0008 3.32 575.35 173.35
ILMN_1249517 Tmem168 0.0010 3.53 225.91 64.01
ILMN_2683802 Nudt9 0.0010 2.69 203.48 75.67
ILMN_1237186 Spint1 0.0011 2.67 152.09 57.02
ILMN_1238360 LOC100042405 0.0011 2.41 941.65 390.74
ILMN_1246127 Prss23 0.0013 2.34 483.67 206.61
ILMN_2678002 Notch2 0.0015 2.66 227.93 85.71
ILMN_2463181 Tnc 0.0016 2.38 317.34 133.06
ILMN_2723024 BC004044 0.0016 2.28 168.75 74.1
ILMN_2878274 Copz2 0.0017 2.18 604.97 277.56
ILMN_2840818 Cmpk 0.0018 2.52 970.31 384.49
ILMN_1226553 Mtap2 0.0020 3.65 154.53 42.28
ILMN_1237216 LOC100047827 0.0020 2.14 831.45 388.45
ILMN_2697020 Bat2d 0.0021 2.12 503.2 237.3
ILMN_2670344 Lrrn2 0.0022 2.26 139.51 61.62
ILMN_2486906 Wisp2 0.0001 − 3.31 140.62 466.12
ILMN_2597606 Gjc2 0.0002 − 3.75 66.05 247.37
ILMN_2684370 Igk-c 0.0002 − 4.42 57.87 255.67
ILMN_1243031 Trrp1 0.0006 − 2.33 51.06 118.96
ILMN_1236368 Orai1 0.0007 − 2.11 79.89 168.37
ILMN_1232263 Kcnk5 0.0009 − 2.33 255.3 594.28
ILMN_1231553 Bdh1 0.0009 − 2.86 49.33 141.27
ILMN_2756435 Cebpb 0.0011 − 2.56 705.42 1802.36
ILMN_2906489 Mocos 0.0011 − 2.65 149.61 396.1
ILMN_2704562 LOC100047628 0.0011 − 4.67 58.56 273.36
ILMN_2968907 Tipin 0.0012 − 2.32 164.69 381.45
ILMN_3099265 Anapc11 0.0013 − 3.42 60.7 207.32
ILMN_2686327 Gas6 0.0014 − 1.63 704.55 1151.77
ILMN_1240289 BC023744 0.0014 − 2.07 138 286.23
ILMN_2760019 Cxcl13 0.0015 − 2.70 99.75 269.81
ILMN_2907214 Tcea3 0.0016 − 2.27 75.55 171.15
ILMN_2687794 Tbx15 0.0016 − 2.32 307.36 714.05
ILMN_1239386 Galntl2 0.0016 − 2.52 115.11 290.55
ILMN_1246999 LOC677205 0.0018 − 2.04 194.58 396.1
ILMN_1232824 D430003P20RIK 0.0018 − 2.82 199.47 562.53
ILMN_2601020 Cnot10 0.0021 − 2.32 144.9 335.67
ILMN_2890935 Avpr1a 0.0021 − 3.19 121.21 386.73
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induced BM formation. STRING analysis showed a tight 
network with enrichment of factors associated with ECM 
organisation, collagen biosynthesis and cell motility, as 
well as cell adhesion, and glycosaminoglycan and heparin 
binding activities (Additional file 7: Figure S5, Additional 
file 8: Table S3).
To establish if expression of identified matrisome 
RNAs is specific to early pregnancy, we assessed 
expression levels at other stages of mammary gland 
development (puberty, adult virgin, early-, mid-, and 
late pregnancy, lactation, and involution) using previ-
ously obtained microarray data from whole BALB/c 
mouse mammary glands [26]. Data were available for 
33 of the 64 Matrisome RNAs (Fig. 4). 18 of 24 RNAs 
upregulated in PAFs showed the strongest abundance 
during times of epithelial outgrowth, puberty (V6) and/
Table 1 (continued)
The table shows the top50 hits (Probe ID) of RNAs that show significant (p < 0.05) differential expression (Fold-change) in fibroblast from 3-days pregnant (Preg) 
compared to virgin control (Crtl) mice, using median signal intensities from 3 individual experiments (biological replicates) and RankP software [18]. Probes have been 
ranked by decreasing fold-change and increasing p-value
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Fig. 3 (A) Immunohistochemical staining for VCAN and ALX4 (arrow heads) around outgrowing ductal epithelium in 3-days pregnant mouse 
mammary glands and in glands from age-matched adult virgin glands (representative images, n = 4 (VCAN) and 3 (ALX4) animals respectively; see 
also Additional file 6: Figure S4). Scale bars are 100 µm. (B) Confirmatory qRT-PCR results for selected RNAs (Gpc1, Wisp2, Alx4, and Vcan) in 3-days 
pregnancy-associated (P) and control fibroblasts (C). Bars represent standard errors (n = 3 animals). (C) Confirmatory qRT-PCR results for selected 
matrisome protein encoding RNAs Col3a1, Col18a1, and Tnc. Bars again represent standard errors (n = 3 animals)
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or early pregnancy (P3) (Adam10, Adam12, Adam23, 
Bmp1, Col3a1, Col5a2, Col13a1, Col18a1, Gpc1, Vcan, 
Col4a1, Agrn, Postn, Fn1, Mfap2, Mfap5, Tnc, Mdk). 
Most were down regulated at mid-pregnancy at onset 
of alveolar differentiation. RNA abundances therefore 
coincided mostly with ductal outgrowth and branching 
initiation. Similarly, 5 of 9 genes (Vtn, Cxcl13, Figf/
Vegfd, Spock2 and Tgfbi) whose RNAs were down regu-
lated in PAFs, were also reduced in P3 glands compared 
to non-pregnant adult glands.
Table 2 Matrisome-encoding RNAs with differential expression in PAFs
The table shows the 74 probes (Probe ID), representing 64 different RNAs, that encode proteins associated with the Matrisome [16] and are differentially expressed 
(p < 0.05) in fibroblasts from 3-days pregnant mouse mammary glands (Preg) compared to fibroblasts isolated from age-matched virgin control glands (Ctrl). Probes 
have been ranked by decreasing fold-change and increasing p-value
Probe ID Gene symbol p‑values (< 0.05) Fold change 
Preg/Ctrl
Probe ID Gene Symbol p‑values (< 0.05) Fold 
change 
Preg/Ctrl
UP ILMN_1225835 Mfap5 0.0296 1.75
ILMN_2635784 Gpc1 0.0001 3.74 ILMN_2774315 Col13a1 0.0300 2.21
ILMN_1247540 Vcan 0.0003 3.1 ILMN_1256970 Adamts18 0.0323 1.71
ILMN_1246127 Prss23 0.0013 2.34 ILMN_2617087 Egln1 0.0347 1.84
ILMN_2463181 Tnc 0.0016 2.38 ILMN_1227502 Il15ra 0.0357 1.53
ILMN_2753809 Mmp3 0.0023 2.12 ILMN_1230599 Adam23 0.0362 1.78
ILMN_1243254 Adam12 0.0030 2.24 ILMN_3008858 Ctsc 0.0371 1.94
ILMN_2463180 Tnc 0.0036 2.4 ILMN_3158499 Mdk 0.0410 1.54
ILMN_2683958 Col3a1 0.0055 1.96 ILMN_2766028 Postn 0.0452 1.67
ILMN_2455596 Adamts18 0.0060 3.23 ILMN_2492264 Wisp1 0.0467 1.81
ILMN_2819929 Plod2 0.0064 1.57 ILMN_2688912 F10 0.0485 1.9
ILMN_1216882 Postn 0.0068 1.9 ILMN_2725927 Serpina3g 0.0488 1.88
ILMN_2769918 Timp1 0.0081 1.72 ILMN_2680415 Sema6d 0.0493 1.61
ILMN_1234487 Angpt2 0.0086 2.44 ILMN_2710698 Fgf21 0.0498 1.53
ILMN_1213850 Col4a3 0.0087 1.82 DOWN
ILMN_3103896 Timp1 0.0091 1.78 ILMN_2486906 Wisp2 0.0001 − 3.31
ILMN_1221670 Col5a2 0.0092 2.29 ILMN_2686327 Gas6 0.0014 − 1.63
ILMN_2728729 Sdc4 0.0093 1.82 ILMN_2760019 Cxcl13 0.0015 − 2.7
ILMN_2735184 Col18a1 0.0116 2.71 ILMN_1231689 Sfrp1 0.0046 − 2.21
ILMN_2769884 Igf1 0.0119 1.43 ILMN_1229370 Podn 0.0094 − 2.85
ILMN_1253797 Slit2 0.0131 2.02 ILMN_1249485 S100g 0.0095 − 2.14
ILMN_2460257 Adam10 0.0154 1.7 ILMN_1219335 Igfbp3 0.0098 − 1.78
ILMN_2617090 Egln1 0.0166 1.84 ILMN_2851288 Ngfr 0.0121 − 1.73
ILMN_2731901 S100a4 0.0171 1.69 ILMN_1238597 Omd 0.0132 − 1.93
ILMN_2715840 C1qc 0.0172 1.79 ILMN_2595664 Dhh 0.0139 − 1.6
ILMN_1240458 Mfap2 0.0188 1.47 ILMN_2697220 Figf/Vegfd 0.0148 − 1.4
ILMN_2901626 Tnfref21 0.0212 1.95 ILMN_2773348 Bmp8a 0.0148 − 2.43
ILMN_2617086 Egln1 0.0224 1.69 ILMN_2461098 Plxnb2 0.0164 − 1.65
ILMN_2718204 Clec11a 0.0235 1.17 ILMN_2910653 Bmp8a 0.0183 − 2.35
ILMN_2671344 Adamts12 0.0242 1.65 ILMN_1251096 Spock2 0.0213 − 1.74
ILMN_1213777 Fgf10 0.0245 1.61 ILMN_2834379 Tgfbi 0.0252 − 1.73
ILMN_1260125 Fn1 0.0252 1.75 ILMN_1259632 Col20a1 0.0253 − 2.07
ILMN_2770429 Plod2 0.0252 1.73 ILMN_1252506 Fbn1 0.0261 − 2.63
ILMN_2638114 Ptn 0.0259 1.37 ILMN_2727503 Igfbp3 0.0297 − 2.63
ILMN_1239380 Leprel2 0.0280 1.71 ILMN_2507286 Tnfsf13b 0.0338 − 1.55
ILMN_2659151 Thbs1 0.0290 1.15 ILMN_2718401 Htra3 0.0392 − 1.82
ILMN_2486186 Tnfrsf1b 0.0291 1.75 ILMN_1234111 Vtn 0.0392 − 1.48
ILMN_1234413 Adamts12 0.0293 1.5 ILMN_1214439 Ltbp1 0.0426 − 1.51
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The matrisome signature of PAFs predicts 
distant‑metastasis free survival (DMFS)
For normal and cancerous epithelium to grow into the 
surrounding stroma, both require stromal remodel-
ling. Tissues often use the same or similar molecular 
mechanisms to drive similar morphological changes. 
We therefore hypothesised that the molecular mecha-
nisms associated with tissue remodelling during early 
mammary lateral branching may also operate during 
human breast cancer progression, enabling and/or sup-
porting cellular invasion and further metastatic spread. 
If this was the case, we would expect the RNA expres-
sion patterns found in our PAFs to be found at least in 
part in breast cancers with a higher risk of progression 
and metastasis formation. To test this hypothesis, we 
assessed whether expression of our 64 gene matrisome 
PAF Up-Regulated
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Fig. 4 Microarray signal intensities of identified PAF-associated core matrisome and matrisome-associated RNAs in whole Balb/C mouse mammary 
glands at different mammary gland developmental stages (Virgin (V) at 6, 10 and 12 weeks, Pregnancy (P) days 1, 2, 3, 8.5, 12.5, 14.5 and 17.5, 
Lactation (Lac) days 1, 3 and 7, and Involution (Inv) days 1, 2, 3, 4 and 20) identified in a previous dataset [26]. Colour intensities reflect signal 
intensities relative to the median (50% percentile) of each RNA across all developmental time points (red: above; blue: below)
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RNA signature correlated with metastatic spread in 1881 
breast cancer patients, using the Gene expression-based 
Outcome for Breast cancer Online (GOBO) webtool [17]. 
Distant metastasis-free survival (DMFS) was used as 
endpoint with a 10-year cut-off point. Fold-change values 
(preg vs ctrl) in expression of each gene from our array 
analysis were used as expression centroids (Table  2). 
Kaplan–Meier analysis showed that the 64 gene PAF 
matrisome signature was a strong univariate prognostic 
indicator of DMFS (LogRank P = 3.36e−5) for all breast 
cancers. The signature remained significant in multivari-
ate analysis including age, tumour size, grade, ER-, and 
LN status (HR = 1.85, 95% CI: 1.39–2.48, P = 2.74e−5) 
(Fig. 5, Additional file 9: Figure S6). Similar results were 
obtained when recurrence-free survival was used as 
an endpoint (Additional file  10: Figure S7). Univariate 
subgroup analysis showed that this signature predicted 
DMFS in the basal (LogRank P = 0.047) and HER2-pos-
itive cancer cohorts (LogRank P = 0.004), though not 
luminal A or B, or normal-like cancer subgroups (Addi-
tional file 9: Figure S6). Correspondingly in multivariate 
analyses, the signature was more powerful in the  ERneg 
cohort (HR = 2.78 (1.65–4.68), P = 1e-04) than in the 
 ERpos cohort (HR = 1.59 (1.13–2.26), P = 0.008) (Fig.  5). 
Additionally, the signature showed prognostic power in 
all histological grades (grade 1: LogRank P = 0.008; grade 
2: LogRank P = 0.008; grade 3: LogRank P = 0.005) (Addi-
tional file 9: Figure S6). Therefore, the signature is a prog-
nostic indicator independent of grade.
An 18‑RNA matrisome signature shows significantly 
increased prognostic power
To identify the most significant contributors to the signa-
ture’s prognostic power, each of the 64 genes was tested 
individually within the GOBO breast cancer dataset. 52 
of them were recognised in this dataset. 48 of 52 reached 
significance (p < 0.05) to stratify patient groups in at least 
one defined breast cancer subgroup. Forty-two were 
consistently associated with either higher or lower lev-
els of DMFS within the subgroups. After multiple test-
ing correction across all gene- and subgroup-analyses, 18 
RNAs retained an adjusted p-value of < 0.05 for at least 
one breast cancer subgroup (Additional file  11: Figure 
S8A). 11 of those 18 RNAs (WISP2, CXCL13, POSTN, 
COL5A2, COL13A1, COL18A1, OMD, CLEC11A, FBN1, 
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Fig. 5 Kaplan–Meier analyses generated using the GOBO online tool and centroid correlation clustering for the 64-gene matrisome signature 
(endpoint: distant metastasis free-survival (DMFS)) in (A) all breast cancers, (B) or the ER-positive (ERpos) and (C) ER-negative (ERneg) subgroup. (D–F) 
Multivariate analyses for the 64-gene signature (Day3 Preg) within same groups as above in the presence of other clinical parameters: size > 20 mm 
(Size), age > 50 years (Age), grade (G3), LN-status (LNneg) and ER-status (ERpos)
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high breast cancer expression of the human orthologues 
associated with poor prognosis, or down-regulated in 
PAFs with low breast cancer expression associated with 
poor prognosis, and therefore potential drivers of pro-
gression within the signature. Contrastingly, the other 
7 RNAs (VCAN, TIMP1, IGF1, SLIT2, TGFBI, CTSC, 
VTN) had up-regulated expression of the RNAs in PAFs 
but high expression of the human orthologues in breast 
cancers was associated with better prognosis, or down-
regulated in PAFs and low expression in breast cancers 
was associated with better prognosis (Additional files 
11: Figures S8, Additional files 12: Figure S9). These dif-
ferences might reflect the controlled nature of mammary 
epithelial branching morphogenesis versus the uncon-
trolled situation in metastasis.
Using again the fold-change expression values of these 
11 + 7 RNAs in PAFs, the univariate prognostic power 
of this combined gene set was comparable to the ini-
tial 64 gene set (LogRank P = 2.45e−06). However, a 
signature using only the above-mentioned 11 RNAs 
showed a strongly increased prognostic power (Log-rank 
P = 7.66e−12). Similarly, a signature using only the resid-
ual seven RNAs also showed stratification ability, but in 
the opposite direction (LogRank P = 6.42e−09) (Addi-
tional file 11: Figure S8B, C).
To improve the prognostic power of the 18 gene signa-
ture, expected centroids for the other seven RNAs were 
reversed. As a result, the prognostic power was signifi-
cantly strengthened for all tumours (LogRank P ≤1e−13) 
(Fig. 6A, B) and remained significant in multivariate anal-
ysis (HR = 2.42 (1.8–3.26), P = 5.61e−09) (Fig. 6B; Addi-
tional file  13: Figure S10). Furthermore, this signature 
was now able to identify tumours with poor DMFS in 
nearly all subgroups analysed  (ERpos,  ERneg,  LNpos,  LNneg, 
 ERpos/LNneg, Grade-2, -3, Luminal A, Luminal B, ErbB2, 
Basal, untreated and tamoxifen-treated) (Fig. 6C-E; Addi-
tional file 14: Figure S11) with the exception of Normal-
like cancers (P = 0.10) and Grade-1 cancers (P = 0.10) 
(Fig. 6E; Additional file 14: Figure S11). Similar, if slightly 
weaker, results were obtained when recurrence-free 
survival was used as end point (LogRank P = 3.08e-08; 
HR = 1.98 (1.55–2.52), P = 3.08e−08) (Additional files 13: 
Figure S10, Additional files 15: Figure S12).
Verification of the signature’s prognostic power using 
the KM‑Plotter database
To verify the prognostic power of our signature, it was 
further tested using ‘Kaplan–Meier Plotter’ [21]. In uni-
variate analysis, this signature stratified breast cancer 
patients according to DMFS in all patients (HR = 1.92 
(1.32–2.79), LogRank P = 0.00047) as well as in  ERpos 
(HR = 1.94 (1.25–3), LogRank P = 0.0025) and  ERneg sub-
groups (HR = 2.61 (1.55–4.39), LogRank P = 0.00018) 
(Fig.  7A-C). Multivariate analyses including ER status, 
Ki-67- and HER2 status confirmed that the signature 
remained a significant predictor of DMFS in all three 
tested cohorts (Fig. 7A-C).
To test for breast cancer-specificity of the signature, we 
analysed its prognostic power also in the gastric, ovar-
ian and lung cancer datasets available in KM-Plotter. The 
signature had significant prognostic power in all data-
sets (ovarian cancer (HR = 1.29 (1.51–1.56), LogRank 
P = 0.0075); lung cancer (HR = 1.72 (1.3–2.26), LogRank 
P = 1e−04)). However, in gastric cancer, higher signa-
ture levels were associated with better prognosis in this 
cohort (HR = 0.64 (0.51–0.82), LogRank P = 0.00029) 
(Fig.  7D–F). Nevertheless, our data show that the 
described changes are not breast cancer-specific.
Discussion
The mammary stroma has been recognised as an impor-
tant determinant of epithelial growth and differentiation 
during normal development as well as cancer progres-
sion [1, 27]. Lateral branch formation and cancer inva-
sion both require major remodelling of the surrounding 
BM and collagen sheath, creating an epithelial growth 
promoting environment. In both cases, fibroblasts play 
significant regulatory roles [11, 28]. We therefore hypoth-
esised that by studying the gene expression changes in 
primary mammary fibroblasts during the initiation of 
pregnancy-associated lateral branching morphogene-
sis, we may identify stromal factors that control normal 
(See figure on next page.)
Fig. 6 (A) List of the 18 genes of the shortened matrisome-signature after multiple testing correction with fold-change expression values used 
for the 18-gene signature. The average fold-change of multiple probes was used for Postn and Timp1 (*). The expression values for the seven RNAs 
below the double lines have been reversed to reflect their tumour suppressor-like behaviour as described in the text. (B) Kaplan–Meier analyses 
(DMFS) generated using the GOBO online tool and centroid correlation clustering for the shortened 18-gene matrisome signature (18-gene sig.) 
in all breast cancers, (C) the ER-positive  (ERpos) and (D) ER-negative  (ERneg) subgroup with associated multivariate analyses in the presence of other 
clinical parameters: size (> 20 mm), age (> 50 years), high grade (G3), LN-status  (LNneg) and ER-status  (ERpos). (E) Bar graph comparing LogRank 
p-values (-log10) from each KM-analysis in the total breast cancer set and all available subgroups obtained for either the 64-gene or 18-gene 
signature (DMFS). The actual p-value for the 18-gene signature for all tumours (red bar) was rounded down by the software to p = 0 as p ≤ 1e−13. 
Red dotted line shows LogRank p = 0.05 with increasing significance above the line
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Fig. 6 (See legend on previous page.)
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ductal branching and also regulate breast cancer inva-
sion, and hence progression to metastatic disease. We 
have identified an 18-gene PAF-associated RNA signa-
ture that can now be used as a starting point for further 
biological tests, studying the functions of the associated 
proteins during mammary branching morphogenesis and 
breast cancer progression. It is so far unclear whether 
the identified RNAs reflect different levels of expression 
within cancer-associated fibroblasts or other stromal 
cells within the individual tumours, or within the cancer 
epithelium itself, e.g. through epithelial-mesenchymal 
transition-type changes. This can now be addressed by 
IHC and in-situ hybridisation in future studies. Impor-
tantly, our data show that the changes of RNA expression 
of these genes are associated with cancer progression in 
a significant number of breast cancers, and could there-
fore play important roles in the control of invasion and/
or metastasis formation.
11 of the 18 genes showed similar expression patterns 
during early pregnancy (5 up- and 6 down-regulated) and 
in poor prognosis breast cancer, and therefore identified 
potential stromal regulators of tissue remodelling during 
normal development and breast cancer progression that 
occur in both biological settings. However, expression of 
A CB
D FE
Total BC cohort P value Hazard Rao ERpos subgroup P value Hazard Rao ERneg subgroup P value Hazard Rao
MKI67 0.9064 0.98 (0.68 - 1.41) MKI67 0.8115 1.07 (0.63 - 1.8) MKI67 0.9114 0.97 (0.58 - 1.63)
ESR1 0.0007 0.54 (0.37 - 0.77) ESR1 NA NA (NA - NA) ESR1 NA NA (NA - NA)
HER2 (ERBB2) 0.0192 1.51 (1.07 - 2.12) HER2 (ERBB2) 0.1451 1.42 (0.89 - 2.27) HER2 (ERBB2) 0.113 1.52 (0.91 - 2.56)
18-gene sig 0.001 1.74 (1.25 - 2.43) 18-gene sig 0.039 1.59 (1.02 - 2.48) 18-gene sig 0.0052 2.09 (1.25 - 3.51)
Fig. 7 Kaplan–Meier analyses generated with KM plotter for the 18-gene signature in (A) all breast cancer patients, (B) ER-positive (ERpos) and 
(C) ER-negative cases (ERneg) using DMFS as endpoint and a 10-year cut-off. Patient cohorts were split using the combined median expression 
levels of all 18 genes with negative weighting for genes associated with good prognosis in the GOBO analysis. ‘High’ and ‘Low’ expression cut-offs 
were chosen automatically by KM-Plotter for best fit. Tables below each graph show the multivariate analysis results, performed in the presence of 
ER status (ESR1), Ki-67 (MKi67)- and HER2 status, and showing hazard ratios and 95%-confidence intervals. (D) Kaplan–Meier plots for the 18-gene 
signature, using progression-free survival as endpoint for the ovarian cancer set, and (E) time to first progression for the lung cancer dataset, as well 
as (F) for gastric cancer patients within KM-Plotter
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the other seven RNAs in the PAFs behaved the opposite 
way to what was expected, being upregulated (Timp1, 
Slit2, Igf1, Vcan, Ctsc) or downregulated (Tgfbi, Vtn) in 
PAFs during pregnancy, but in the human breast cancers 
this expression pattern was associated with improved 
rather than poor DMFS (see Additional file  11: Fig-
ure S8C). These RNAs therefore behaved diametrically 
opposed to our initial hypothesis. We hypothesise that 
these seven identified factors reflect some of the differ-
ences between the ‘controlled invasion’ of normal mam-
mary branching morphogenesis and cancer cell invasion, 
and therefore may identify mechanisms that prevent 
mammary epithelial cells from growing uncontrollably 
into surrounding stroma. One unexpected finding was 
the correlation between increased Vcan RNA expression 
and better DMFS in  ERpos and  LNneg cancers as VCAN 
protein expression in peritumoral stroma of the breast 
has previously been associated with poor prognosis in 
 LNneg breast cancers [29]. That study analysed a mix of 
60 grade 1–3 breast cancers in total with six showing 
increased VCAN staining. Unfortunately, no further clin-
ical data (e.g. ER-status) or association of VCAN stain-
ing with grade were available for this patient group. This 
contradiction may reflect a divergence between RNA and 
protein expression. However, in the mouse mammary 
gland, VCAN is strongly co-expressed and colocalises 
with FBLN2 [13], a protein required for BM integrity, 
around newly outgrowing ducts during puberty and early 
pregnancy [14]. We have recently shown that in breast 
cancer FBLN2 together with COLIV is reduced in areas 
of invasion compared to neighbouring morphological 
normal tissue, with high Fbln2 RNA levels showing sig-
nificant association with better DMFS in breast cancers 
of low and intermediate grade in KM-Plotter. In contrast, 
in high grade cancers FBLN2 RNA expression was asso-
ciated with poor prognosis [14]. This could reflect dif-
ferent protein requirements at the various progression 
stages, where FBLN2 presence may suppress tumour 
invasion in the early stages but may enable cancer cells to 
survive and form metastases once invasion has occurred. 
This could either be through expression of those stromal 
proteins by the malignant cells themselves or by inducing 
their local microenvironment to express these proteins, 
as the tumour ECM is a product of both the tumour 
epithelial and stromal cells [30]. Hence, our results may 
reflect a similar association for VCAN.
Collagens form a key part of the extracellular matrix, 
requiring extensive remodelling during tissue turno-
ver during cancer progression and development. This 
is reflected in our 18-gene signature, with three of five 
RNAs upregulated in PAFs and for which higher expres-
sion in breast cancers was associated with poor prognosis 
encoded collagen proteins (Col5a2, Col13a1, Col18a1). 
COLV is an essential regulator of collagen fibrillo-
genesis [31] and is expressed in breast cancer desmo-
plastic stroma in response to invasive carcinoma [32]. 
Consistent with our data, COL5A2 expression itself is 
upregulated in epithelial cells of breast invasive ductal 
carcinoma compared to DCIS [33]. Similarly, COLXIII 
has been detected in several cancers at the invasive front 
[34] and its expression in breast cancers is associated 
with increased invasion and metastasis [35]. Interest-
ingly, recent evidence has linked COL18A1 to the mam-
mary stem cell-niche with Col18a1−/− mice developing 
fewer terminal end buds and branch points. Oestrogen 
and progesterone induce WNT4, which activates the 
protease ADAM-TS18 in myoepithelial cells, leading to 
remodelling of the BM and activation of mammary stem 
cells through binding of ADAM-TS18 to COL18A1 in 
the stem cell niche [36]. It is therefore interesting to note 
that Adamts-18 was also significantly induced in PAFs 
together with Col18a1 (Table 2).
The Wnt-signalling pathway is an important activator 
of mouse mammary branching morphogenesis [37], and 
two further RNAs in our signature indicated an involve-
ment of our PAFs in the activation of the Wnt-pathway 
and mammary stem cells: Postn and Sfrp1. Postn is neces-
sary for correct collagen fibril assembly [38] and for met-
astatic colonisation, recruiting Wnt-ligands for cancer 
stem cell maintenance [39]. It has been detected in can-
cer-associated fibroblasts of invasive breast carcinoma 
[40, 41], and overexpression in human mammary epi-
thelial cells enhances breast tumour growth and metas-
tasis [38]. Sfrp1 is a negative regulator of Wnt-signalling, 
which was downregulated in our PAFs, and reduced 
SFRP1 was associated with poor DMFS. This is consist-
ent with SFRP1 being epigenetically silenced in ~ 75% of 
invasive breast cancers [42].
By focussing our study purely on the matrisome, our 
signature did not show any similarities with previously 
described prognostic RNA signatures, such as the Core 
Serum Response signature by Chang et  al. [43], which 
was derived from cultured serum-activated fibroblasts. 
Our study deliberately avoided in  vitro culturing, and 
instead used RNA from freshly isolated primary PAFs. 
Our RNA data therefore should reflect the in vivo situa-
tion more closely [44]. Further, in contrast to other pub-
lished signatures [45], our signature is also not driven by 
descriptors of cellular proliferation and ER-signalling and 
is hence independent of grade.
In recent years, several molecular diagnostic RNA sig-
natures for breast cancer progression have been devel-
oped and are now widely commercially available (for 
example Endopredict [46] and OncotypeDX [47, 48]). All 
of these have been specifically designed and approved to 
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assess the risk of metastasis formation in early low-grade 
 ERpos/HER2neg/LNneg breast cancer patients, which rep-
resent 60–70% of all newly diagnosed cases. Since our 
signature performs particularly well in high grade,  ERneg, 
and  HER2pos breast cancer cohorts, it might complement 
these established tools in providing crucial information 
about the risk of distant metastasis formation for therapy 
decision-making in these difficult to treat patient groups. 
Notably, the 18-gene set had prognostic significance 
using the different analysis methods of GOBO and KM 
plotter, and performed well when compared to Endo-
predict and OncotypeDX, using the GOBO Gene Set 
Analysis Tool (Additional file 16: Table S4), which allows 
for analysis of weighted expression (rather than the cen-
troidal analysis method of ‘Sample Prediction’, as shown 
in Figs. 5 and 6). We acknowledge that the current com-
parison is imperfect. Nevertheless, our results show that 
our matrisome derived gene set performs better, particu-
larly in HER2 and  ERneg and high-grade tumours than 
proliferation-associated signatures. Therefore, several 
approaches could now be taken to develop an optimised 
score.
Conclusions
In summary, we identified potential new candidates 
involved in a complex system of stromal-controlled epi-
thelial branching, and provide a testable novel dataset 
for further analyses of stromal-epithelial interaction and 
stromal-controlled breast cancer progression. In addi-
tion, we have provided a potential new tool to iden-
tify breast cancer patients, particularly within the  ERneg 
and  HER2pos cohorts that have a significantly altered 
risk of developing metastases, and may therefore be 
further developed into a diagnostic tool to aid therapy 
decision-making.
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Additional file 1: Figure S1. Immunohistochemical analysis of 3-days 
pregnant mouse (n = 1 animal, 3rd gland) mammary gland and age-
matched adult virgin glands showing the changes of matrix- and base-
ment membrane-associated proteins (COLI, COLVI, BMP1, FBLN5, and 
AGRN). Scale bars are 50 µm.
Additional file 2: Table S1. Table with total and average counts (and 
standard deviation) of identified 3D-structures from triplicate co-culture 
experiments. Student T-tests were performed to compare co-cultures with 
fibroblasts from P3 and age-matched control (V12) mice.
Additional file 3: Figure S2. Immunohistochemical analysis using the 
contralateral inguinal mammary glands for validation of the specific 
expression of FBLN2 around the outgrowing ductal epithelium as a 
marker of early pregnancy in all three mice used for the isolation of 3-days 
pregnancy-associated fibroblasts (P3 A‑C) and their age-matched control 
counterparts (Ctrl A‑C). Similar results were obtained for COLIV. Scale bars 
are 100 µm.
Additional file 4: Figure S3. Microarray signal intensities of markers for 
fibroblasts (Pdgfra (probe_ID ILMN_1235932), Col1a1 (ILMN_2687872), 
Col1a2 (ILMN_1253806), Serpinh1 (Hsp47; ILMN_2822850), Vim 
(ILMN_2451022), S100a4 (ILMN_2731901)), fibroblast/myoepithelial 
cells (Acta2 (smooth-muscle actin; ILMN_2693895; ILMN_27103549)), 
myopepithelial cells (Krt5 (ILMN_2740939), Krt14 (ILMN_2722616)), luminal 
epithelial cells (Krt8 (ILMN_1221157), Krt18 (ILMN_2711267)), vascular/
endothelial cells (Pecam1 (Cd31; ILMN_2700982; ILMN_3147074), Cdh5 
(VE-cadherin)), macrophages (Emr1 (ILMN_1216880; ILMN_2847787)), as 
well as leukocytes (PtprC (Cd45; ILMN_1212836; ILMN_2671984)) from 
PAFs (Day3 Pregnancy) and from fibroblasts isolated from age-matched 
virgin counterparts (Adult Virgin). Bars represent standard errors (n = 3 
animals). Identically labelled columns represent the signal intensities from 
individual probes for the same RNA.
Additional file 5: Table S2. All 897 probes with differential abundance 
in pregnancy-associated fibroblasts (p-value < 0.05) as identified by 
RankP software analysis [18]. Probes have been ranked by decreasing 
fold-change.
Additional file 6: Figure S4. Immunohistochemical analysis using the 
contralateral inguinal mammary glands for validation of the specific 
expression of VCAN around the outgrowing ductal epithelium in the 
three mice used for the isolation of 3-days pregnancy-associated fibro-
blasts (P3 A‑C) and their age-matched control counterparts (Ctrl A‑C). 
Similar results were obtained for ALX4. Note that for ALX4 Ctrl A and P3 A 
show the same sections as in Fig. 3A. Scale bars are 100 µm.
Additional file 7: Figure S5. STRING analysis using the 64-gene matri-
some genes showing their predicted protein–protein interactions. The 
table below shows the two most significantly over-represented Gene 
Ontology (GO) biological processes, molecular functions, and local 
network clusters with enrichment-level (strength) and false-discovery 
rate (FDR) for each grouping. The ‘Count in gene set’ numbers represent 
the number of genes within our signature associated with a particular GO 
group out of the total of genes associated with this group.
Additional file 8: Table S3. Table of enriched Biological Processes, 
Molecular Functions and Network Clusters in the 64 gene set as defined 
by STRING analysis.
Additional file 9: Figure S6. Kaplan–Meier analyses generated using 
the GOBO online tool for the 64-gene matrisome signature (DMFS) in all 
patients and each breast cancer subgroup classified based on ER status, 
Tumor grade, LN status and molecular subtyping according to Hu et al. 
[49–51]or PAM50 (Luminal A, Luminal B, Her-2, Basal and Normal-like) [52], 
as well as Tamoxifen treatment.
Additional file 10: Figure S7. Kaplan–Meier analyses generated using 
the GOBO online tool for the 64-gene matrisome signature (RFS) in all 
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patients and each breast cancer subgroup classified based on ER status, 
Tumor grade, LN status and molecular subtyping according to Hu et al. 
[49–51]or PAM50 (Luminal A, Luminal B, Her-2, Basal and Normal-like) [52], 
as well as Tamoxifen treatment.
Additional file 11: Figure S8. (A) List of the multiple-correction adjusted 
p-values for those genes with a p-value of p < 0.05 in at least one breast 
cancer subtype. Colours show the association of either high (red) or low 
(blue) expression for each gene that is associated with poor DMFS. (B) 
List of the same RNAs with fold-change expression values between PAFs 
(Preg) and control (Ctrl) fibroblasts. The average fold-change of multiple 
probes was used for Postn and Timp1 (*). (C) Kaplan–Meier analysis for 
gene signatures of either those 11 genes for which the expression (up 
or down) during pregnancy is also associated with poor DMFS in breast 
cancer (11_gene_sig; WISP2, CXCL13, POSTN, COL5A2, COL13A1, COL18A1, 
OMD, CLEC11A, FBN1, SFRP1, SPOCK2), and the seven genes for which the 
expression (up or down) during pregnancy is associated with improved 
DMFS (7_gene_sig; VCAN, TIMP1, IGF1, SLIT2, TGFBI, CTSC, VTN), or a com-
bination of the two (11 + 7_gene_sig).
Additional file 12: Figure S9. Kaplan–Meier analyses generated using 
the GOBO online tool for each single gene of the shortened 18-gene 
signature (DMFS) in the total breast cancer dataset (showing non-adjusted 
p-values). Cut-offs of median expression for each gene were automatically 
chosen by GOBO for best separation into two survival groups.
Additional file 13: Figure S10. Multivariate Analysis for 18-gene signa-
ture (18_gene_sig) in the total breast cancer cohort (Total BC cohort), 
 ERpos (ER_pos) or  ERneg (ER_neg) cancer patients in the presence of 
other clinical parameters: size > 20 mm (Size), age > 50 years (Age), grade 
(G3), LN-status (LNneg) and ER-status (ERpos), using either DMFS or RFS as 
endpoint (10-year cut-off ).
Additional file 14: Figure S11. Kaplan–Meier analyses generated using 
the GOBO online tool for the shortened 18-gene matrisome signature 
(DMFS) in all patients and each breast cancer subgroup classified based 
on ER status, Tumor grade, LN status and molecular subtyping accord-
ing to Hu et al. [49–51]or PAM50 (Luminal A, Luminal B, Her-2, Basal and 
Normal-like) [52], as well as Tamoxifen treatment.
Additional file 15: Figure S12. Kaplan–Meier analyses generated using 
the GOBO online tool for the shortened 18-gene matrisome signature 
(RFS) in all patients and each breast cancer subgroup classified based on 
ER status, Tumor grade, LN status and molecular subtyping according to 
Hu et al. [49–51] or PAM50 (Luminal A, Luminal B, Her-2, Basal and Normal-
like) [52], as well as Tamoxifen treatment.
Additional file 16: Table S4. Comparison of the 18-gene signature 
(18_gene_sig) with the 21 gene signature from OncotypeDX and the 
8 gene signature from Endopredict, using ‘Gene Set Analysis’ tool in 
GOBO, which allowed for analysis of weighted expression as previously 
defined [46, 48]. DMFS was chosen as endpoint (10-year cut-off ). p-values 
for Kaplan–Meier analysis are shown for the total cohort and each 
breast cancer subgroup. Yellow highlights subgroups for which only the 
18-gene signature shows a significant stratification (p < 0.05), while green 
highlights those subgroups, in which the 18-gene signature showed 
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